IP20-14: Assessment of Disease Recurrence in Complete Responders after Stopping Sequential Gemcitabine and Docetaxel in patients with High-Risk non-muscle invasive bladder cancer.

IP20-14: Assessment of Disease Recurrence in Complete Responders after Stopping Sequential Gemcitabine and Docetaxel in patients with High-Risk non-muscle invasive bladder cancer.

Friday, May 15, 2026 3:30 PM to 5:30 PM · 1 hr. 59 min. (America/New_York)
146A
Abstract

Registered attendees

Alexander Kutikov
Alexander Kutikov
Chair, Urology and Urologic OncologyFox Chase Cancer Center
David Chen
David Chen
ProfessorFox Chase Cancer Center-Temple Health Urologic Institute
David Han
David Han
FellowFox Chase-Temple Urologic Institute

Log in

See all the content and easy-to-use features by logging in or registering!